A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. The researchers report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa.